Abstracts
Worldwide, colorectal cancer is the third most commonly occurring cancer. Local recurrence and distance metastasis, especially in patients with low rectal cancers, present the main problems for surgeons. Even after undergoing total mesorectal excision (TME), the local recurrence rate for stage III patients is 20–30%. The available treatments of rectal cancers are far from satisfactory; the 5- and 10-year surgical rates are 35% and 22%, respectively. To improve the local control and long-term survival rates, it is necessary for patients with resectable stage II–III cancers to receive neoadjuvant therapy before undergoing surgery. Per the evidence, preoperative chemoradiotherapy (CRT) can significantly reduce the local recurrence of locally advanced rectal cancers and increase the rates of anus preservation. Hence, most guidelines, such as those of the National Comprehensive Cancer Network (NCCN), the European Society for Medical Oncology (ESMO), and the American Cancer Society (ACS), have strongly recommended the implementation of presurgery CRT as standard neoadjuvant therapy for locally advanced rectal cancers.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86. https://doi.org/10.1002/ijc.29210.
Dbeis R, Smart NJ, Daniels IR. Focusing the management of rectal cancer. Ann Transl Med. 2016;4(24):521. https://doi.org/10.21037/atm.2016.11.80.
Trakarnsanga A, Ithimakin S, Weiser MR. Treatment of locally advanced rectal cancer: controversies and questions. World J Gastroenterol. 2012;18(39):5521–32. https://doi.org/10.3748/wjg.v18.i39.5521.
Li Y, Wang J, Ma X, Tan L, Yan Y, Xue C, Hui B, Liu R, Ma H, Ren J. A review of neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Int J Biol Sci. 2016;12(8):1022–31. https://doi.org/10.7150/ijbs.15438.
Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med. 1991;324:709–15.
Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355(11):1114–23.
NIH consensus conference: adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990;264:1444–50.
Madoff RD. Chemoradiotherapy for rectal cancer—when, why, and how? N Engl J Med. 2004;351(17):1790–2.
Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R, German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–40.
Belluco C, Forlin M, Olivieri M, Cannizzaro R, Canzonieri V, Buonadonna A, Bidoli E, Matrone F, Bertola G, De Paoli A. Long-term outcome of rectal cancer with clinically (EUS/MRI) metastatic mesorectal lymph nodes treated by neoadjuvant chemoradiation: role of organ preservation strategies in relation to pathologic response. Ann Surg Oncol. 2016;23:4302–9. https://doi.org/10.1245/s10434-016-5451-5.
Arbea L, Ramos LI, Martínez-Monge R, Moreno M, Aristu J. Intensity-modulated radiation therapy (IMRT) vs. 3D conformal radiotherapy (3DCRT) in locally advanced rectal cancer (LARC): dosimetric comparison and clinical implications. Radiat Oncol. 2010;5:1–9.
Petrelli F, Sgroi G, Sarti E, Barni S. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer. Ann Surg. 2013;263(3):458–64. https://doi.org/10.1097/SLA.0000000000000368.
Heald RJ. The ‘Holy Plane’ of rectal surgery. J R Soc Med. 1988;81(9):503–8.
Frasson M, Garcia-Granero E, Roda D, Flor-lorente B. Preoperative chemoradiation may not always be needed for patients with T3 and T2N+ rectal cancer. Cancer. 2011;117:3118–25. https://doi.org/10.1002/cncr.25866.
Weiser MR, Zhang Z, Schrag D. Locally advanced rectal cancer: time for precision therapeutics. Am Soc Clin Oncol Educ Book. 2015;35:e192–6.
Hong TS, Kachnic LA. Preoperative chemoradiotherapy in the management of localized rectal cancer: the new standard. Gastrointest Cancer Res. 2007;1:49–56.
Kouyama Y, Kudo S-E, Miyachi H, Ichimasa K, Hisayuki T, Oikawa H, Matsudaira S, Kimura YJ, Misawa M, Mori Y, Kodama K, Kudo T, Hayashi T, Wakamura K, Katagiri A, Hidaka E, Ishida F, Hamatani S. Practical problems of measuring depth of submucosal invasion in T1 colorectal carcinomas. Int J Color Dis. 2016;31:137–46.
Ong MLH, Schofield JB. Assessment of lymph node involvement in colorectal cancer. World J Gastrointest Surg. 2016;8:179–92.
Samdani T, Garcia-Aguilar J. Imaging in rectal cancer: magnetic resonance imaging versus endorectal ultrasonography. Surg Oncol Clin N Am. 2014;23:59–77.
Ferrari L, Fichera A. Neoadjuvant chemoradiation therapy and pathological complete response in rectal cancer. Gastroenterol Rep. 2015;3(4):277–88. https://doi.org/10.1093/gastro/gov039.
Lombardi R, Cuicchi D, Pinto C, Di Fabio F, Iacopino B, Neri S, Tardio ML, Ceccarelli C, Lecce F, Ugolini G, Pini S, Di Tullio P, Taffurelli M, Minni F, Martoni A, Cola B. Clinically-staged T3N0 rectal cancer: is preoperative chemoradiotherapy the optimal treatment? Ann Surg Oncol. 2010;17:838–45. https://doi.org/10.1245/s10434-009-0796-7.
Cedars Sinai. Rectal cancer. NCCN Clinical Practice Guidelines in Oncology, versuib 2. 2017. Retrieved from http://www.cedars-sinai.edu/Patients/Programs-and-Services/Colorectal-Cancer-Center/Services-and-Treatments/Rectal-Cancer.aspx
Jo P, Nietert M, Gusky L, Kitz J, Conradi LC, Müller-Dornieden A, Schüler P, Wolff HA, Rüschoff J, Ströbel P, Grade M, Liersch T, Beißbarth T, Ghadimi MB, Sax U, Gaedcke J. Neoadjuvant therapy in rectal cancer - biobanking of preoperative tumor biopsies. Sci Rep. 2016;6:35589. https://doi.org/10.1038/srep35589.
Snijders HS, Leersum NJ, Van Henneman D, Vries AC, De Tollenaar RAEM, Stiggelbout AM, Wouters MW, Dekker JWT. Optimal treatment strategy in rectal cancer surgery: should we be cowboys or chickens? Ann Surg Oncol. 2015;22(11):3582–9. https://doi.org/10.1245/s10434-015-4385-7.
Brændengen M, Tveit KM, Berglund Å, Birkemeyer E, Gunilla Frykholm LP, Wiig JN, Byström P, Bujko K, Glimelius B. Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol. 2008;26(22):3687–94. https://doi.org/10.1200/JCO.2007.15.3858.A.
Gunderson LL, Sosin H. Areas of failure found at reoperation (secondor symptomatic look) following curative surgery for adenocarcinoma ofthe rectum: clinicopathologic correlation and implications foradjuvant therapy. Cancer. 1974;34:1278–92.
Higgins GA, Humphrey EW, Dwight RW, et al. Preoperative radiation and surgery for cancer of the rectum. Veterans administration surgical oncology group trial II. Cancer. 1986;58(2):352–9.
Izar F, Fourtanier G, Pradere B, et al. Pre-operative radiotherapy as adjuvant treatment in rectal cancer. Cancer. 1992;16(1):106–11. Discussion 111–2.
Hyams DM, Mamounas EP, Petrelli N, et al. A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectum: a progress report of National Surgical Breast and Bowel Project Protocol R-03. Dis Colon Rectum. 1997;40(2):131.
Aklilu M, Eng C. The current landscape of locally advanced rectal cancer. Nat Rev Clin Oncol. 2011;8(11):649–59.
Lai LL, Fuller CD, Kachnic LA, et al. Can pelvic radiotherapy be omitted in select patients with rectal cancer? Semin Oncol. 2006;33(11):70–4.
Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30(16):1926–33. https://doi.org/10.1200/JCO.2011.40.1836.
Bosset JF, Pavy JJ, Hamers HP, et al. Determination of the optimal dose of 5-fluorouracil when combined with low dose D,L-leucovorin and irradiation in rectal cancer: results of three consecutive phase II studies. Eur J Cancer. 1993;29A:1406–10.
Bosset JF, Calais G, Mineur L, et al. Enhanced tumoricidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results—EORTC 22921. J Clin Oncol. 2005;23:5620–7.
Bosset JF, Calais G, Daban A, et al. Pre-operative chemoradiotherapy versus preoperative radiotherapy in rectal cancer patients: assessment of acute toxicity and treatment compliance—report of the 22921 randomised trial conducted by the EORTC Radiotherapy Group. Eur J Cancer. 2004;40:219–24.
Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery: the clue to pelvic recurrence? Br J Surg. 1982;82:613–6.
Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med. 1997;336:980–7.
Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, van Krieken JH, Leer JW, van de Velde CJ. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345:638–46.
Shi C, Zhou H, Li X, Cai Y. A retrospective analysis on two-week short-course pre-operative radiotherapy in elderly patients with resectable locally advanced rectal cancer. Sci Rep. 2016;6:37866. https://doi.org/10.1038/srep37866.
Wang L, Li YH, Cai Y, Zhan TC, Gu J. Intermediate neoadjuvant radiotherapy combined with total mesorectal excision for locally advancd rectal cancer: outcomes after a median follow-up of 5 years. Clin Colorectal Cancer. 2016;15(2):152–7.
Liu G, Yan J, He Q, An X, Pan Z, Ding P. Effect of neoadjuvant chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a meta-analysis. Gastroenterol Res Pract. 2016;2016:1–10. https://doi.org/10.1155/2016/1798285.
Allegra CJ, Yothers G, O’Connell MJ, Beart RW, Wozniak TF, Pitot HC, Shields AF, Landry JC, Ryan DP, Arora A, Evans LS, Bahary N, Soori G, Eakle JF, Robertson JM, Moore DF, Mullane MR, Marchello BT, Ward PJ, Sharif S, Roh MS, Wolmark N. Neoadjuvant 5-FU or capecitabine plus radiation with or without oxaliplatin in rectal cancer patients: a phase III randomized clinical trial. J Natl Cancer Inst. 2015;107:djv248.
Aschele C, Cionini L, Lonardi S, Pinto C, Cordio S, Rosati G, Artale S, Tagliagambe A, Ambrosini G, Rosetti P, Bonetti A, Negru ME, Tronconi MC, Luppi G, Silvano G, Corsi DC, Bochicchio AM, Chiaulon G, Gallo M, Boni L. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol. 2011;29:2773–80.
Gérard J-P, Azria D, Gourgou-Bourgade S, Martel-Lafay I, Hennequin C, Etienne P-L, Vendrely V, François E, de La Roche G, Bouché O, Mirabel X, Denis B, Mineur L, Berdah J-F, Mahé M-A, Bécouarn Y, Dupuis O, Lledo G, Seitz J-F, Bedenne L, Juzyna B, Conroy T. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol. 2012;30:4558–65.
Machiels JP, Sempoux C, Scalliet P, et al. Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. Ann Oncol. 2007;18:738–44.
Bertolini F, Chiara S, Bengala C, et al. Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab,and pelvic radiotherapy: a phase II study in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2009;73:466–72.
Rodel C, Arnold D, Hipp M, et al. Phase I-II trial of cetuximab,capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer. Int J Radiat Oncol Biol Phys. 2008;70:1081–6.
Horisberger K, Treschl A, Mai S, et al. Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a phase II MARGIT trial. Int J Radiat Oncol Biol Phys. 2009;74:1487–93.
Kim SY, Hong YS, Kim DY, et al. Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter phase II study. Int J Radiat Oncol Biol Phys. 2011;81(3):677–83.
Dewdney A, Cunningham D, Tabernero J, et al. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). J Clin Oncol. 2012;30(14):1620–7.
Willett CG, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Sahani DV, Lahdenranta J, Chung DC, Fischman AJ, Lauwers GY, Shellito P, Czito BG, Wong TZ, Paulson E, Poleski M, Vujaskovic Z, Bentley R, Chen HX, Clark JW, Jain RK. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol. 2009;27:3020–6.
Crane CH, Eng C, Feig BW, Das P, Skibber JM, Chang GJ, Wolff RA, Krishnan S, Hamilton S, Janjan NA, Maru DM, Ellis LM, Rodriguez-Bigas MA. Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2010;76:824–30.
Velenik V, Ocvirk J, Music M, Bracko M, Anderluh F, Oblak I, Edhemovic I, Brecelj E, Kropivnik M, Omejc M. Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study. Radiat Oncol. 2011;6:105.
Salazar R, Capdevila J, Laquente B. A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features. BMC Cancer. 2015;15:60.
Gasparini G, Torino F, Ueno T, Cascinu S, Troiani T, Ballestrero A, Berardi R, Shishido J, Yoshizawa A, Mori Y, Nagayama S, Morosini P, Toi M. A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer. Angiogenesis. 2012;15:141–50.
Landry JC, Feng Y, Cohen SJ, Staley CA. Phase 2 study of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: ECOG 3204. Cancer. 2013;119(8):1521–7.
Ludmir EB, Palta M, Willett CG, Czito BG. Total neoadjuvant therapy for rectal cancer: an emerging option. Cancer. 2017;123:1497–506.
Sclafani F, Cunningham D. Neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer. Future Oncol. 2014;10(14):2243–57.
Fernandez-Martos C, Pericay C, Aparicio J, et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant hemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. J Clin Oncol. 2010;28(5):859–65.
Ishii Y, Hasegawa H, Endo T, et al. Medium-term results of neoadjuvant systemic chemotherapy using irinotecan, 5-fluorouracil,and leucovorin in patients with locally advanced rectal cancer. Eur J Surg Oncol. 2010;36:1061–5.
Uehara K, Hiramatsu K, Maeda A, et al. Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapyfor poor-risk rectal cancer: N-SOG 03 phase II trial. Jpn J Clin Oncol. 2013;43:964–71.
Hasegawa J, Nishimura J, Mizushima T, et al. Neoadjuvant capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high-risk localized rectal cancer. Cancer Chemother Pharmacol. 2014; 73:1079–87.
Schrag D, Weiser MR, Goodman KA, et al. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol. 2014;32:513–8.
Trakarnsanga A, Gonen M, Shia J, et al. What is the significance of the circumferential margin in locally advanced rectal cancer after neoadjuvant chemoradiotherapy? Ann Surg Oncol. 2013;20:1179–84.
Glimelius B, Tiret E, Cervantes A, et al. Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(6):81–8.
Wang Q-X, Li S-H, Zhang X, Xie L, Cai P-Q, An X, et al. Identification of locally advanced rectal cancer with low risk of local recurrence. PLoS One. 2015;10(1):e0117141.
MERCURY Study Group. Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study. Radiology. 2007;243(1): 132–9.
Mass M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11:835–44.
Sun YS, Zhang XP, Tang L, Ji JF, Gu J, Cai Y, Zhang XY. Locally advanced rectal carcinoma treated with preoperative chemotherapy and radiation therapy: preliminary analysis of difussion-weighted MR imaging for early detection of tumor histopathologic downstaging. Radiology. 2009;254:170–8.
Maas M, Beets-Tan RG, Lambregts DM, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol. 2011;29(35):4633.
Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro U Jr, Silva e Sousa AH Jr, Campos FG, Kiss DR, Gama- Rodrigues J. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long term results. Ann Surg. 2004;240:711–7.
Hernandez-Carcia I, Viudez A, Suarez J, et al. Clinical complete response in locally advanced rectal cancer: can we offer a wait-and-see policy? Ann Oncol. 2013;24(3):853.
Kwak YK, Kim K, Lee JH, et al. Timely tumor response analysis after preoperative chemoradiotherapy and curative surgery in locally advanced rectal cancer: a multi-institutional study for optimal surical timing in rectal cancer. Radiother Oncol. 2016;119(3):512–8.
Lefevre JH, Mineur L, Kotti S, et al. Effect of interval (7 or 11 weeks) between neoaduavant radiochemotherapy and surgery on complete pathologic response in rectal cancer: a multicenter, randomized, controlled trial (GRECCAR-6). J Clin Oncol. 2016;34:3773.
Bujko K, Nowacki MP, Michalski W, Bebenek M, Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006;93:1215–23. https://doi.org/10.1002/bjs.5506.
Trotti A, Barthel JS, Kim CJ, Yeatman TJ, Coppola D, Trotti A, Williams B. Local excision of T2 and T3 rectal cancers after downstaging chemoradiation. Ann Surg. 2001;234(3):352–9. https://doi.org/10.1097/00000658-200109000-00009.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Gu, J. (2018). Neoadjuvant Therapy for Locally Advanced Rectal Cancer. In: Kim, N., Sugihara, K., Liang, JT. (eds) Surgical Treatment of Colorectal Cancer. Springer, Singapore. https://doi.org/10.1007/978-981-10-5143-2_8
Download citation
DOI: https://doi.org/10.1007/978-981-10-5143-2_8
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-10-5142-5
Online ISBN: 978-981-10-5143-2
eBook Packages: MedicineMedicine (R0)